West Pharmaceutical Services (WST)

NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-15

$384.02+0.26%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge West Pharmaceutical Services’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.3%

+10% or more+5%0%−5%−10% or less

9.99 → 10.03 EPS · FY ending Dec 31, 2027 · 11 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 11 to 11; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Full-year 2026 adjusted EPS near $8.57	A primary condition in West Pharmaceutical Services's published investment case. The stated target is ~$8.57.	Intact	EPS falls below $8.0 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Q2 2026 EPS near $2.12	A supporting condition in West Pharmaceutical Services's published investment case. The stated target is ~$2.12.	Intact	Q2 EPS falls below $2.0	Diluted EPS: $2.15 per share FY2026-Q2; GAAP. Published target: ~$2.12. The target does not explicitly identify fiscal versus calendar quarters. Source published Jul 23, 20262.15 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5b871954-b43f-4906-b161-2510274c449e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full-year 2026 revenue near $3.32 billion	A primary condition in West Pharmaceutical Services's published investment case. The stated target is ~$3.32B.	Intact	revenue falls below $3.1 billion in FY26	Revenue: $872.3M FY2026-Q2; GAAP. Published target: ~$3.32B. Target period is not explicitly aligned with this observation. Source published Jul 23, 2026872,300,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5b871954-b43f-4906-b161-2510274c449e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$10.03

$9.62 → $10.03 · observed estimates

FY2027 revenue$3.58B

$3.54B → $3.58B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.62	$3,537,409,940	16 / 15
2026-07-25	$9.79	$3,557,698,427	10 / 12
2026-07-26	$9.92	$3,575,292,615	10 / 12
2026-07-27	$9.92	$3,584,233,360	15 / 14
2026-07-28	$9.92	$3,584,233,360	15 / 14
2026-07-29	$9.92	$3,575,292,615	10 / 12
2026-07-30	$9.94	$3,582,888,250	16 / 15
2026-07-31	$9.95	$3,579,308,836	10 / 12
2026-08-01	$9.95	$3,579,308,836	10 / 12
2026-08-02	$9.96	$3,587,120,750	16 / 15
2026-08-03	$9.96	$3,587,120,750	16 / 15
2026-08-04	$9.95	$3,579,308,836	10 / 12
2026-08-05	$9.95	$3,579,308,836	10 / 12
2026-08-06	$9.96	$3,587,120,750	16 / 15
2026-08-08	$9.95	$3,579,308,836	10 / 12
2026-08-09	$9.95	$3,579,308,836	10 / 12
2026-08-10	$9.96	$3,587,120,750	16 / 15
2026-08-12	$9.95	$3,579,308,836	10 / 12
2026-08-13	$9.96	$3,587,120,750	16 / 15
2026-08-14	$9.95	$3,579,308,836	10 / 12
2026-08-15	$9.95	$3,579,308,836	10 / 12
2026-08-16	$9.95	$3,579,308,836	10 / 12
2026-08-17	$9.95	$3,579,308,836	10 / 12
2026-08-18	$9.95	$3,579,308,836	10 / 12
2026-08-19	$9.95	$3,579,308,836	10 / 12
2026-08-20	$9.98	$3,583,869,763	10 / 12
2026-08-21	$9.98	$3,583,869,763	10 / 12
2026-08-22	$9.98	$3,583,869,763	10 / 12
2026-08-23	$9.98	$3,583,869,763	10 / 12
2026-08-24	$9.98	$3,583,869,763	10 / 12
2026-08-25	$9.98	$3,583,869,763	10 / 12
2026-08-26	$9.98	$3,583,869,763	10 / 12
2026-08-27	$9.98	$3,583,869,763	10 / 12
2026-08-28	$9.98	$3,583,869,763	10 / 12
2026-08-29	$9.98	$3,583,869,763	10 / 12
2026-08-30	$9.98	$3,583,869,763	10 / 12
2026-08-31	$9.98	$3,583,869,763	10 / 12
2026-09-01	$9.98	$3,583,869,763	10 / 12
2026-09-02	$9.98	$3,583,869,763	10 / 12
2026-09-03	$9.98	$3,583,869,763	10 / 12
2026-09-04	$9.98	$3,583,869,763	10 / 12
2026-09-05	$9.98	$3,583,869,763	10 / 12
2026-09-06	$9.98	$3,583,869,763	10 / 12
2026-09-07	$9.98	$3,583,869,763	10 / 12
2026-09-08	$9.98	$3,583,869,763	10 / 12
2026-09-09	$9.98	$3,583,869,763	10 / 12
2026-09-10	$9.99	$3,582,532,843	10 / 12
2026-09-11	$9.99	$3,582,532,843	11 / 13
2026-09-12	$9.99	$3,582,532,843	11 / 13
2026-09-13	$9.99	$3,582,532,843	11 / 13
2026-09-14	$9.99	$3,582,532,843	11 / 13
2026-09-15	$9.99	$3,582,532,843	11 / 13
2026-09-16	$9.99	$3,582,532,843	11 / 13
2026-09-17	$9.99	$3,582,532,843	11 / 13
2026-09-18	$9.99	$3,582,532,843	11 / 13
2026-09-19	$9.99	$3,582,532,843	11 / 13
2026-09-20	$9.99	$3,582,532,843	11 / 13
2026-09-21	$9.99	$3,582,532,843	11 / 13
2026-09-22	$9.99	$3,582,532,843	11 / 13
2026-09-23	$10.00	$3,583,980,035	11 / 13
2026-09-24	$10.00	$3,583,980,035	11 / 13
2026-09-25	$10.00	$3,583,980,035	11 / 13
2026-09-26	$10.00	$3,583,980,035	11 / 13
2026-09-27	$10.00	$3,583,980,035	11 / 13
2026-09-28	$10.00	$3,583,980,035	11 / 13
2026-09-29	$10.00	$3,583,980,035	11 / 13
2026-09-30	$10.00	$3,583,980,035	11 / 13
2026-10-01	$10.00	$3,583,980,035	11 / 13
2026-10-02	$10.00	$3,583,980,035	11 / 13
2026-10-03	$10.00	$3,583,980,035	11 / 13
2026-10-04	$10.00	$3,583,980,035	11 / 13
2026-10-05	$10.00	$3,583,980,035	11 / 13
2026-10-06	$10.00	$3,583,980,035	11 / 13
2026-10-07	$9.99	$3,583,980,035	11 / 13
2026-10-08	$10.01	$3,583,980,035	11 / 13
2026-10-09	$10.01	$3,583,980,035	11 / 13
2026-10-10	$10.01	$3,583,980,035	11 / 13
2026-10-11	$10.01	$3,584,113,368	11 / 13
2026-10-12	$10.01	$3,584,113,368	11 / 13
2026-10-13	$10.01	$3,584,113,368	11 / 13
2026-10-14	$10.03	$3,584,266,702	11 / 13
2026-10-15	$10.03	$3,584,266,702	11 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	3	0
2026-06-01	14	3	1
2026-07-01	14	2	1
2026-08-01	14	2	0
2026-09-01	16	2	0
2026-10-01	16	1	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades2 maintains

Recent actions · Sep 16–Oct 15 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 7 · prior Jun 9

$400.00 → $440.00+10.0%

Morgan StanleySep 22 · prior Jul 9

$365.00 → $400.00+9.6%

$0$242.00$484.00

2 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Full-year 2026 adjusted EPS near $8.57Direct metric needs a verified mapping
Q2 2026 EPS near $2.12Diluted EPS: $2.15 per share
Full-year 2026 revenue near $3.32 billionRevenue: $872.3M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.9%Typical daily move · historical

Downside history

-24.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

West Pharmaceutical Services outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on consistent revenue and earnings growth. The current thesis is intact, supported by strong recent financial performance and management's commitment to increasing guidance.

What's priced into West Pharmaceutical Services

The market currently reflects an expensive valuation compared to peers, driven by a durable premium. There is an expectations gap, indicating that investors may be anticipating continued strong performance.

What the fundamentals likely do

Management is on track to increase revenue and earnings guidance for 2026, with recent results showing strong growth. However, there is a moderate risk due to potential economic headwinds that could impact performance.

What West Pharmaceutical Services hinges on

The thesis hinges on maintaining positive momentum in the healthcare sector and the ability of WST to meet or exceed raised guidance. Additionally, broader economic indicators, such as the jobs report, will be crucial in shaping future performance.